Cardinal Health Reports Record Operating Income and Raises Fiscal 2027 Guidance
Cardinal Health (CAH) delivered a strong first quarter for fiscal 2027, characterized by record quarterly operating income of $1.0 billion and a 28% increase in non-GAAP diluted EPS to $3.26. Revenue grew 5% to $67.5 billion, fueled primarily by the Pharmaceutical and Specialty Solutions segment, which saw an 18% surge in specialty revenue driven by high demand for GLP-1 weight-loss and diabetic medications. Despite headwinds from the Inflation Reduction Act (IRA) impacting top-line pharmaceutical revenue and rising petroleum costs affecting medical product distribution margins, management raised its full-year non-GAAP EPS guidance to a range of $12.80 to $13.00. The company also demonstrated strong capital management, executing $500 million in share repurchases and maintaining a robust cash position of $5.3 billion.
Topics: EPS GLP-1 Demand Operating Income Pharmaceutical Sales Revenue Growth